65. Primary immunodeficiency Clinical trials / Disease details


Clinical trials : 482 Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-003327-15-NL
(EUCTR)
21/02/202219/01/2022Thymosin-a1 in immunodeficiency associated mood disordersAn open-label, 8-week, proof of concept trial on thymosin-a1 (thymalfasin) in the treatment of primary antibody deficiency (PAD) associated mood disorders (TIDAM18). - TIDAM Primary immunodeficiency;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Trade Name: Thymalfasin
Product Name: Thymafalsin
INN or Proposed INN: THYMALFASIN
Other descriptive name: Zadaxin
Erasmus MCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Phase 2Netherlands